SCHEMBL3395669

SCHEMBL3395669

COc1cc(Cn2nnc3c(Cl)nc(N)nc32)cc(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 10/20 0.52
ADORA2A P29274 9/20 0.52
ADORA2B P29275 9/20 0.52
ADORA1 P30542 9/20 0.52
PDE8B O95263 2/20 0.50
HSP90AA1 P07900 3/20 0.46
HSP90AB1 P08238 3/20 0.46
TRAP1 Q12931 2/20 0.42
HSP90B1 P14625 1/20 0.42
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3392762 0.89 PDE8B (0.63) ADORA3ADORA2AADORA2BADORA1PDE8B
SCHEMBL3396109 0.85 HSP90AA1 (0.65) ADORA3ADORA2AADORA2BADORA1PDE8B
SCHEMBL3391863 0.82 HSP90AB1 (0.45) ADORA3ADORA2AADORA2BADORA1PDE8B
SCHEMBL3395517 0.82 HSP90AB1 (0.50) ADORA3ADORA2AADORA2BADORA1PDE8B
SCHEMBL3393789 0.81 HSP90AB1 (0.50) ADORA3ADORA2AADORA2BADORA1PDE8B
SCHEMBL3394682 0.81 HSP90AA1 (0.50) ADORA3ADORA2AADORA2BADORA1PDE8B
SCHEMBL3392701 0.80 HSP90AB1 (0.67) ADORA3ADORA2AADORA2BADORA1PDE8B
SCHEMBL3393873 0.79 ADORA2A (0.62) ADORA3ADORA2AADORA2BADORA1ALDH1A1
SCHEMBL3395507 0.78 HSP90AB1 (0.74) ADORA2AHSP90AA1HSP90AB1TRAP1HSP90B1
SCHEMBL4046670 0.77 ADORA2A (0.85) ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070111997-A1 Triazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-05-17 US disclosed
US-7129244-B2 Triazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2006-10-31 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113339-A1 Triazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113339-A1 Triazolopyrimidines and related analogs as HSP90-inhibitors HSP90AB2P, HSP90AB1, HSP90AA1 ADORA3 4757/4885ADORA2A 4615/4885ADORA2B 4709/4885
US-20070111997-A1 Triazolopyrimidines and related analogs as HSP90-inhibitors HSP90AB2P, HSP90AB1, HSP90AA1 ADORA3 4757/4885ADORA2A 4615/4885ADORA2B 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.